CPRX — CATALYST PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1369568 ·
Last close
$31.33
Market Cap
$3.83B
52W High
$32.56
52W Low
$22.16
ADV30
2,898,707
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 149,390,000 | 134,915,000 | 73,232,000 | 63,734,000 | 1,147,610,000 | 755,859,000 | 134,913,000 |
| Dec 2025 | 152,613,000 | 126,539,000 | 61,846,000 | 52,698,000 | 1,103,979,000 | 709,171,000 | 149,711,000 |
| Sep 2025 | 148,392,000 | 125,738,000 | 66,267,000 | 52,783,000 | 1,051,602,000 | 689,892,000 | 131,357,000 |
| Jun 2025 | 146,563,000 | 125,949,000 | 66,298,000 | 52,108,000 | 971,915,000 | 652,800,000 | 115,888,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$208,670,000
Investing CF
$-58,000
Financing CF
$-16,994,000
CapEx
$-379,000
Dividends Paid
—
Buybacks
$-25,300,000
EPS Diluted TTM
$1.69
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$474,188,000
Inventory
$37,166,000
Receivables
$128,266,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
$283,515,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$596,958,016
EBITDA
$305,828,992
Free Cash Flow
$171,809,872
Enterprise Value
$3,072,451,840
Total Cash
$755,859,008
Total Debt
$2,681,000
Shares Out
122,380,992
Trailing EPS
$1.73
Book Value
$8.29
ROE
24.5%
ROA
16.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 588,989,000 | 257,778,000 | 214,326,000 | 1,103,979,000 | 149,711,000 | — | 208,670,000 |
| Dec 2024 | 491,734,000 | 195,124,000 | 163,889,000 | 851,411,000 | 123,779,000 | — | 239,808,000 |
| Dec 2023 | 398,204,000 | 86,812,000 | 71,410,000 | 470,114,000 | 82,233,000 | — | 143,600,000 |
| Dec 2022 | 214,203,000 | 101,838,000 | 83,079,000 | 375,630,000 | 75,209,000 | — | 116,047,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$3.14
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc. | $3.88B | $36.78 | — |
| ACAD | ACADIA PHARMACEUTICALS INC | $3.64B | $21.26 | — |
| EWTX | Edgewise Therapeutics, Inc. | $3.61B | $33.56 | — |
| AMRX | Amneal Pharmaceuticals, Inc. | $4.08B | $12.79 | — |
| ERAS | Erasca, Inc. | $3.58B | $11.50 | — |
News headlines (Yahoo Finance, 1h cache)
GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal
2026-05-20 21:54 · Yahoo
Angelini Buyout And FIRDAPSE Settlement Reframe Catalyst Pharmaceuticals Story
2026-05-20 20:08 · Yahoo
CPRX or UTHR: Which Is the Better Value Stock Right Now?
2026-05-14 15:40 · Yahoo
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
2026-05-12 15:18 · Yahoo
Catalyst (CPRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
2026-05-11 22:30 · Yahoo
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates
2026-05-11 22:05 · Yahoo
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
2026-05-11 20:12 · Yahoo
Angelini Pharma agrees $4.1bn Catalyst Pharmaceuticals acquisition
2026-05-11 09:27 · Yahoo
Catalyst Pharmaceuticals Buyout And FIRDAPSE Patents Reframe Investor Outlook
2026-05-10 07:10 · Yahoo
This Biotech Stock Has Soared 175%. Here’s Why One Fund Still Sold $3 Million Worth
2026-05-09 16:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.